Literature DB >> 29433681

Zerumbone targets the CXCR4-RhoA and PI3K-mTOR signaling axis to reduce motility and proliferation of oral cancer cells.

Nur Syafinaz Zainal1, Chai Phei Gan1, Beng Fye Lau2, Pei San Yee1, Kai Hung Tiong3, Zainal Ariff Abdul Rahman4, Vyomesh Patel1, Sok Ching Cheong5.   

Abstract

BACKGROUND: The CXCR4-RhoA and PI3K-mTOR signaling pathways play crucial roles in the dissemination and tumorigenesis of oral squamous cell carcinoma (OSCC). Activation of these pathways have made them promising molecular targets in the treatment of OSCC. Zerumbone, a bioactive monocyclic sesquiterpene isolated from the rhizomes of tropical ginger, Zingiber zerumbet (L.) Roscoe ex Sm. has displayed promising anticancer properties with the ability to modulate multiple molecular targets involved in carcinogenesis. While the anticancer activities of zerumbone have been well explored across different types of cancer, the molecular mechanism of action of zerumbone in OSCC remains largely unknown.
PURPOSE: Here, we investigated whether OSCC cells were sensitive towards zerumbone treatment and further determined the molecular pathways involved in the mechanism of action.
METHODS: Cytotoxicity, anti-proliferative, anti-migratory and anti-invasive effects of zerumbone were tested on a panel of OSCC cell lines. The mechanism of action of zerumbone was investigated by analysing the effects on the CXCR4-RhoA and PI3K-mTOR pathways by western blotting.
RESULTS: Our panel of OSCC cells was broadly sensitive towards zerumbone with IC50 values of less than 5 µM whereas normal keratinocyte cells were less responsive with IC50 values of more than 25 µM. Representative OSCC cells revealed that zerumbone inhibited OSCC proliferation and induced cell cycle arrest and apoptosis. In addition, zerumbone treatment inhibited migration and invasion of OSCC cells, with concurrent suppression of endogenous CXCR4 protein expression in a time and dose-dependent manner. RhoA-pull down assay showed reduction in the expression of RhoA-GTP, suggesting the inactivation of RhoA by zerumbone. In association with this, zerumbone also inhibited the PI3K-mTOR pathway through the inactivation of Akt and S6 proteins.
CONCLUSION: We provide evidence that zerumbone could inhibit the activation of CXCR4-RhoA and PI3K-mTOR signaling pathways leading to the reduced cell viability of OSCC cells. Our results suggest that zerumbone is a promising phytoagent for development of new therapeutics for OSCC treatment.
Copyright © 2017 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Akt; Migration; Oral squamous cell carcinoma; Proliferation; RhoA; Zerumbone

Mesh:

Substances:

Year:  2017        PMID: 29433681     DOI: 10.1016/j.phymed.2017.12.011

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  8 in total

1.  Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models.

Authors:  Pei San Yee; Nur Syafinaz Zainal; Chai Phei Gan; Bernard K B Lee; Kein Seong Mun; Mannil Thomas Abraham; Siti Mazlipah Ismail; Zainal Ariff Abdul Rahman; Vyomesh Patel; Sok Ching Cheong
Journal:  Target Oncol       Date:  2019-04       Impact factor: 4.493

Review 2.  Plants of the Genus Zingiber: A Review of Their Ethnomedicine, Phytochemistry and Pharmacology.

Authors:  Miao Deng; Xuan Yun; Shurui Ren; Zhixing Qing; Fenglian Luo
Journal:  Molecules       Date:  2022-04-29       Impact factor: 4.927

3.  Transcriptional Biomarkers in Oral Cancer: An Integrative Analysis and the Cancer Genome Atlas Validation.

Authors:  Kinjal D Patel; Hemangini H Vora; Prabhudas S Patel
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

Review 4.  Gingers and Their Purified Components as Cancer Chemopreventative Agents.

Authors:  John F Lechner; Gary D Stoner
Journal:  Molecules       Date:  2019-08-07       Impact factor: 4.411

Review 5.  Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials.

Authors:  Choudhary Harsha; Kishore Banik; Hui Li Ang; Sosmitha Girisa; Rajesh Vikkurthi; Dey Parama; Varsha Rana; Bano Shabnam; Elina Khatoon; Alan Prem Kumar; Ajaikumar B Kunnumakkara
Journal:  Int J Mol Sci       Date:  2020-05-06       Impact factor: 5.923

6.  Zerumbone Promotes Cytotoxicity in Human Malignant Glioblastoma Cells through Reactive Oxygen Species (ROS) Generation.

Authors:  Mohammad Jalili-Nik; Mohammad Montazami Sadeghi; Elmira Mohtashami; Hamid Mollazadeh; Amir R Afshari; Amirhossein Sahebkar
Journal:  Oxid Med Cell Longev       Date:  2020-05-06       Impact factor: 6.543

7.  Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma.

Authors:  Julia Schnoell; Isabella Stanisz; Bernhard J Jank; Victoria Stanek; Rainer Schmid; Markus Brunner; Gregor Heiduschka; Ulana Kotowski
Journal:  Invest New Drugs       Date:  2021-10-06       Impact factor: 3.651

8.  The Combination of Zerumbone with 5-Fluorouracil for Sensitizing Colorectal Cancer-Associated Fibroblasts to Treatment.

Authors:  Sima Nobari; Rezvan Najafi; Ali Mahdavinezhad; Akram Jalali; Razieh Amini
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-11       Impact factor: 2.650

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.